Despite the fact that the latest wave of obesity medicines frequently results in significant weight reduction, many patients are curious about what actually could happen when they stop using their medication. At the end of the 36-week period, 670 people had achieved a significant weight loss of 20.9 percent on average. It was found that the majority of the trial participants were female, with a median age of 48 and a mean weight of 107.3 kg at the beginning of the most recent study. The rest of the findings are genuinely intriguing yet shocking.
Why did people typically gain weight when they stopped using new medications for obesity?
The research focused on the administration of tirzepatide, which is the ingredient that is found in Zepbound, a new weight loss medication manufactured by Eli Lilly and licensed by the American government just one month ago. A placebo was administered to half of the participants in the study, while the other half continued to take Zepbound as they had been doing previously. Every single participant was given instructions to eat 500 fewer calories on a daily basis than they burned off and to engage in physical activity for a minimum of 150 minutes each week. Participants on Zepbound kept going to reduce their body weight, reaching a final weight that was 25.3 percent lighter than where they had begun. Those who were given a placebo, on the other hand, recovered nearly fifty percent of the weight that they had lost at the conclusion of the 88-week period, resulting in a weight loss that was 9.9 percent below their own baseline.
Semaglutide is the active component of Wegovy and Novo Nordisk’s Ozempic, which, similar to Zepbound, are just a few examples of referred to as “GLP-1 agonists” that operate by imitating the activity of a hormone that produces glucose, delays the digestion, and suppresses hunger. Semaglutide is also the active ingredient in Zepbound.
[…] medications, including potent anti-obesity medications such as semaglutide, have demonstrated that weight is substantially regained, explained the study authors, led by Louis Aronne at Weill Cornell Medicine, New York.
The thing with GLP-1 agonists is that they have been shown to reduce the likelihood of coronary artery disease that is connected with obesity; nevertheless, investigations have shown that they also increase the incidence of intestinal problems. Consequently, there is more to it than meets the eye, and there is an absolute requirement for ongoing studies on drugs that aid in weight reduction.
